comparemela.com

Latest Breaking News On - Melissa vadnais - Page 1 : comparemela.com

Ensuring Access And Approval For Innovative Therapies In Scleroderma

Clinical research and development programs for innovative therapies in scleroderma must accommodate the diverse data needs of multiple stakeholders.

05 24 21 -- Eli Lilly Weighs The Benefits & Challenges Of Head-To-Head Trials

05.24.21 Eli Lilly Weighs The Benefits & Challenges Of Head-To-Head Trials     This report provides data on 240 service provider encounters with 18 electronic clinical outcome assessment/electronic patient reported outcomes (eCOA/ePRO) systems. eCOA/ePRO providers: Learn how your company performs against competitors. Discover where performance exceeds expectations so you can differentiate your offerings from competitors. For sponsors/CROs: Compare your company’s outsourcing philosophy to that of the broader industry. Evaluate your provider selection process. Explore new providers and understand how they have performed for industry peers. Clinical Leader In this webinar segment, Tero Laulajainen, VP and head of global clinical science and operations for UCB, and Hassan Kadhim, global head of clinical trial business capabilities, clinical innovation, and industry collaborations at Bristol-Myers Squibb, discuss the guidance issued by regulato

04 12 21 -- Best Practices For Implementing Decentralized Clinical Trials

04.12.21 Best Practices For Implementing Decentralized Clinical Trials   Sponsor Is clinical development prepared for the paradigm shift caused by COVID-19? The pandemic has forced the industry to reevaluate how to engage with patients and acquire patient data without direct, in-person access. Biopharmaceutical companies, medical device companies, and CROs from around the world were surveyed to explore the impact on clinical trials in this new paradigm and gain insights into their experiences operationalizing trials in a pandemic. Learn more. Featured Editorial By Sam Brown, Nell Haslett-Brousse, Ryan Quinn, and John Theodore, Point B While the experience design related to the patient is paramount to the adoption of decentralized clinical trial technology, the interrelated experience and incentives for all stakeholders must be fully aligned to realize the full benefits of these platforms.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.